Lucent Diagnostics a Quanterix Brand

Lucent Diagnostics a Quanterix Brand

Lucent Diagnostics, a Quanterix brand, is committed to transforming Alzheimer’s detection and diagnosis through cutting edge biomarker testing. The company is pioneering ultra-sensitive, blood-based biomarker testing for Alzheimer’s disease. Lucent’s goal is to make highly-sensitive, accessible blood tests the new standar ...
Products

Recently updated

Alzheimer’s Blood Test
LucentAD p-Tau 217

LucentAD p-Tau 217 is a simple blood-based test that measures phosphorylated Tau 217 (p-Tau 217), which is a biomarker associated with amyloid pathology, a hallmark of Alzheimer’s disease. LucentAD p-Tau 217 leverages the combination of Quanterix’s ultra-sensitive Simoa technology and J&J Innovative Medicine’s extensively studied p-Tau 217 antibodies to provide high accuracy with a simplified workflow.
More details

Alzheimer’s Blood Test
LucentAD Complete

LucentAD Complete is a highly sensitive blood test that measures multiple Alzheimer ’s-related biomarkers, including p-Tau 217, AB 42/40, GFAP, and NfL. This multi-analyte algorithmic approach reduces the diagnostic uncertainty associated with single-biomarker tests, making it an essential tool for earlier Alzheimer’s disease evaluation.
More details

Clinical Laboratory

Alzheimer’s Blood Test
LucentAD p-Tau 217

LucentAD p-Tau 217 is a simple blood-based test that measures phosphorylated Tau 217 (p-Tau 217), which is a biomarker associated with amyloid pathology, a hallmark of Alzheimer’s disease. LucentAD p-Tau 217 leverages the combination of Quanterix’s ultra-sensitive Simoa technology and J&J Innovative Medicine’s extensively studied p-Tau 217 antibodies to provide high accuracy with a simplified workflow.
More details

Alzheimer’s Blood Test
LucentAD Complete

LucentAD Complete is a highly sensitive blood test that measures multiple Alzheimer ’s-related biomarkers, including p-Tau 217, AB 42/40, GFAP, and NfL. This multi-analyte algorithmic approach reduces the diagnostic uncertainty associated with single-biomarker tests, making it an essential tool for earlier Alzheimer’s disease evaluation.
More details
Copyright © 2000-2026 TradeMed.com. All rights reserved. | Terms And Conditions